Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scienture Holdings Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Scienture Holdings's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4E4 vs WGRX, HEWA, BLMH: Buyback Yield % Comparison
For the Pharmaceutical Retailers subindustry, Scienture Holdings's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scienture Holdings Buyback Yield % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Scienture Holdings's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Scienture Holdings's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scienture Holdings (FRA:4E4) has a Buyback Yield % of -142.58 as of Jul. 26, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Scienture Holdings and its competitors. According to the industry distribution chart, Scienture Holdings ranks #267 out of 274 companies in the Healthcare Providers & Services industry, placing it in the top 97.4%.
Is Scienture Holdings' Buyback Yield % too high?
Scienture Holdings' current Buyback Yield % is -142.58. Based on the distribution chart, Scienture Holdings ranks #267 out of 274 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Scienture Holdings has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Scienture Holdings' Buyback Yield % compare to WGRX and HEWA?
According to the Healthcare Providers & Services industry distribution chart, Scienture Holdings ranks #267 out of 274 companies for Buyback Yield %. This places Scienture Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Healthcare Providers & Services company?
A good Buyback Yield % depends on the Healthcare Providers & Services industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Scienture Holdings and its competitors. Scienture Holdings's current Buyback Yield % is -142.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scienture Holdings stock overvalued right now?
Scienture Holdings (FRA:4E4) has a current Buyback Yield % of -142.58. The stock's GF Value™ is €0.18, compared to a current price of €0.19 — trading 7.4% above its estimated fair value. The current Buyback Yield % is -142.58. Scienture Holdings' overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Scienture Holdings (FRA:4E4), the current Buyback Yield % is -142.58 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scienture Holdings (FRA:4E4) Overvalued in 2026?
Based on GuruFocus' analysis, Scienture Holdings stock appears to be overvalued.
The current stock price of €0.19 is trading 7.4% above its estimated GF Value™ of €0.18.
Key valuation signals for FRA:4E4:
Buyback Yield %: -142.58
GF Value™: €0.18 vs. price of €0.19 (7.4% above fair value)
No single metric tells the full story. See the FRA:4E4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
47GF Score
Get the complete analysis for FRA:4E4
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4E4 has been successfully added to your 
